The UK has approved a new drug product for glaucoma diseases, delivered with Novelia®


The Novelia® system is the first and only preservative-free multidose eyedropper UK-approved for a glaucoma drug

Thanks to its unique innovative design, Novelia® has been approved as packaging component and delivery system of multidose drug product formulated without preservatives.

Novelia_detail web

“This approval sets an important milestone for Novelia®” said Fanny Sellier, Category Manager of Nemera. “We’re excited to make it easier for UK patients to use preservative-free glaucoma drugs”


One way of keeping multi-dose eye droppers safe for patients is to add preservatives to the formulation. However, the use of preservatives can cause allergies or ocular irritation, and some can even cause a toxic response, damaging patients’ eyes[*]. Any such reactions are even more an issue for patients who rely on the long term use of eye drops for chronic conditions, like glaucoma.

The alternative way to keep eye droppers contamination-free is by the intelligent use of technology. Rather than relying on the anti-microbial properties of preservatives to kill bacterias, the ideal approach is to prevent their entry into the bottle in the first place.

A viable alternative to the use of sterile filters for multi-dose preservative free eye droppers is a non-return valve system used in conjunction with a silicone membrane to filter the returning air. Novelia®: a multidose closing tip system avoids the need for preservatives in the drug and prevents bacterial contamination over the duration of treatment.

About Nemera

Nemera is a world leader in the design, development and manufacturing of drug delivery solutions. Its expertise covers all five modes of delivery: Ophthalmic (preservative-free multidose eyedroppers), Parenteral (autoinjectors, pens, safety devices & implanters), Pulmonary (pMDIs, DPIs), Nasal/Buccal/Auricular (spray pumps, actuators, valves, etc.), Dermal /Transdermal (airless & atmospheric dispensers). Nemera provides solutions for the pharmaceutical industry, including standard innovative products, the development of proprietary devices and contract manufacturing.

[*] Report of the International Dry Eye Workshop. Ocul Surf 2007; 5[2]; 65-204.